Publications by authors named "Sergio Sanchez-Alvarez"
Low-density lipoprotein cholesterol (LDLc) is the lead effector of atherosclerosis and main treatment target. Bempedoic acid is a novel oral drug in the therapeutic armamentarium which is able to reduce LDLc. The objectives of this study were (1) to select the potential patients for administering bempedoic acid such as those with a very high cardiovascular risk in which objectives of LDLc were not achieved despite conventional treatment with PCSK9 inhibitors (PCSK9i) and/or statins and ezetimibe and (2) to estimate the cost-effectiveness of bempedoic acid in different scenarios.
View Article and Find Full Text PDFArticle Synopsis
- Monoclonal antibodies targeting PCSK9 significantly lower LDL cholesterol levels by about 55% in patients, but their impact on other lipid parameters like cholesterol remnants is less clear.
- A study analyzing data from 652 patients across 14 hospitals in Spain showed that treatment with PCSK9 inhibitors not only reduced LDL cholesterol but also led to significant decreases in other lipid measures, including the triglycerides-to-HDL ratio and cholesterol remnants.
- The findings indicate that over one-third of patients achieved LDL cholesterol below 55 mg/dl and lower cholesterol remnants, suggesting that PCSK9 inhibitors are effective in managing lipid residual risk as well as LDL cholesterol levels.
Background: Previous evidence supports that monoclonal antibodies that inhibit the proprotein convertase subtilisin/kexin type 9 (PCSK9) reduce low-density lipoprotein cholesterol (LDLc) by 50%-65%, regardless of baseline treatments. We tested possible sex differences in a multicentre registry of real-world patients treated with PCSK9 inhibitors.
Methods: This is a multicentre and retrospective study of 652 patients initiating treatment with any PCSK9 inhibitor in 18 different hospitals.